Rhonda Cooper-DeHoff, PharmD, MS
Dr. Cooper-DeHoff is Associate Director of the Center for Pharmacogenomics and Associate Professor in the Department of Pharmacotherapy and Translational Research and the Department of Pharmaceutics, College of Pharmacy, and in the Division of Cardiovascular Medicine, College of Medicine, at the University of Florida.
- 2014 – Fellow of the American College of Clinical Pharmacy
- 2009 – Research featured by the American Society of Hypertension
- 2008 – Received the Clinical Science Award from the Consortium for Southeastern Hypertension Control
- 2007 – Named Fellow of the American Heart Association
|PharmD||University of California at San Francisco, School of Pharmacy||Pharmacy|
|MS||University of Florida||Medical Sciences/Clinical Investigation|
- Dr. Cooper-DeHoff’s research interests include hypertension, metabolic syndrome, and diabetes, and she is the principal investigator for the NIH-funded Career Development Award (K23) entitled “Metabolic Effects of Antihypertensive Drugs.” She was an investigator of the International Verapamil Trandolapril Study (INVEST), which evaluated hypertension treatments in elderly coronary artery disease patients, and is a co-investigator on two NIH grants evaluating pharmacogenetic associations in hypertension. She is a member of the American Heart Association, American Society of Hypertension, American College of Cardiology, and Florida Society of Hospital Pharmacists. Cooper-DeHoff serves as a scientific reviewer for several journals, including Circulation, Annals of Pharmacotherapy, Lancet, and many others.
- American Society of Hypertension
- American Heart Association
- American College of Cardiology
- Florida Society of Hospital Pharmacists
- North Central Florida Society of Hospital Pharmacists
- Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, et al.; IGNITE Network. JACC Cardiovasc Interv. 2018;11(2):181-91.
- Sphingolipid metabolic pathway impacts thiazide diuretics blood pressure response: insights from genomics, metabolomics, and lipidomics. Shahin MH, Gong Y, Frye RF, Rotroff DM, Beitelshees AL, Baillie RA, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Motsinger-Reif A, Fiehn O, Cooper-DeHoff RM, Han X, Kaddurah-Daouk R, Johnson JA. J Am Heart Assoc. 2017 Dec 29;7(1). pii: e006656.
- Whole transcriptome sequencing analyses reveal molecular markers of blood pressure response to thiazide diuretics. Sá ACC, Webb A, Gong Y, McDonough CW, Datta S, Langaee TY, Turner ST, Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, Johnson JA. Sci Rep. 2017;7(1):16068.
- Genetic variants associated with uncontrolled blood pressure on thiazide diuretic/β-blocker combination therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) trials. Magvanjav O, Gong Y, McDonough CW, Chapman AB, Turner ST, Gums JG, Bailey KR, Boerwinkle E, Beitelshees AL, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, Johnson JA. J Am Heart Assoc. 2017;6(11). pii: e006522.
- Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. Mehanna M, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Schwartz GL, Johnson JA, Turner ST, Cooper-DeHoff RM. J Clin Hypertens (Greenwich). 2017;19(12):1301-8.
- Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease: long-term mortality results from the INternational VErapamil-trandolapril STudy US cohort. Wokhlu A, Smith SM, Gong Y, Handberg EM, Elgendy IY, Bavry AA, Cooper-DeHoff RM, Pepine CJ. J Hypertens. 2017 Sep 21. [Epub ahead of print]
- Branched-chain amino acid, meat intake and risk of type 2 diabetes in the Women’s Health Initiative. Isanejad M, LaCroix AZ, Thomson CA, Tinker L, Larson JC, Qi Q, Qi L, Cooper-DeHoff RM, Phillips LS, Prentice RL, Beasley JM. Br J Nutr. 2017;117(11):1523-30.
- Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K, Laufs U, Werner C, Koenig W, Rothenbacher D, Mons U, Breitling LP, Brenner H, Jennings RT, Petrakis I, Triem S, Klug M, Filips A, Blankenberg S, Waldeyer C, Sinning C, Schnabel RB, Lackner KJ, Vlachopoulou E, Nygård O, Svingen GFT, Pedersen ER, Tell GS, Sinisalo J, Nieminen MS, Laaksonen R, Trompet S, Smit RAJ, Sattar N, Jukema JW, Groesdonk HV, Delgado G, Stojakovic T, Pilbrow AP, Cameron VA, Richards AM, Doughty RN, Gong Y, Cooper-DeHoff R, et al. Lancet Diabetes Endocrinol. 2017;5(7):534-43.
- Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network. Sperber NR, Carpenter JS, Cavallari LH, J Damschroder L, Cooper-DeHoff RM, Denny JC, Ginsburg GS, Guan Y, Horowitz CR, Levy KD, Levy MA, Madden EB, Matheny ME, Pollin TI, Pratt VM, Rosenman M, Voils CI, W Weitzel K, Wilke RA, Ryanne Wu R, Orlando LA. BMC Med Genomics. 2017;10(1):35.
- Genome-wide study of resistant hypertension identified from electronic health records. Dumitrescu L, Ritchie MD, Denny JC, El Rouby NM, McDonough CW, Bradford Y, Ramirez AH, Bielinski SJ, Basford MA, Chai HS, Peissig P, Carrell D, Pathak J, Rasmussen LV, Wang X, Pacheco JA, Kho AN, Hayes MG, Matsumoto M, Smith ME, Li R, Cooper-DeHoff RM, Kullo IJ, Chute CG, Chisholm RL, Jarvik GP, Larson EB, Carey D, McCarty CA, Williams MS, Roden DM, Bottinger E, Johnson JA, de Andrade M, Crawford DC. PLoS ONE. 2017;12(2):e0171745.
- Effect of low-furanocoumarin hybrid grapefruit juice consumption on midazolam pharmacokinetics. Kawaguchi-Suzuki M, Nasiri-Kenari N, Shuster J, Gmitter FG Jr, Cancalon P, de Oliveria F, Kight J, Handberg EM, Pepine CJ, Frye RF, Cooper-DeHoff RM. J Clin Pharmacol. 2017;57(3):305-11.
- Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. Weng L, Gong Y, Culver J, Gardell SJ, Petucci C, Morse AM, Frye RF, Turner ST, Chapman A, Boerwinkle E, Gums J, Beitelshees AL, Borum PR, Johnson JA, Garrett TJ, McIntyre LM, Cooper-DeHoff RM. Metabolomics. 2016;12(10). pii:160.
- Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach.de Oliveira FA, Shahin MH, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, Cooper-DeHoff RM. Metabolomics. 2016;12(8). pii: 129.
- Mortality risk associated with resistant hypertension among women: analysis from three prospective cohorts encompassing the spectrum of women’s heart disease. Smith SM, Huo T, Gong Y, Handberg E, Gulati M, Merz CN, Pepine CJ, Cooper-DeHoff RM. J Womens Health (Larchmt). 2016;25(10):996-1003.
Please click here for a list of Rhonda Cooper-DeHoff’s industry relationships.